Vaccine availability for kids to pave way for school reopening: AIIMS chief




Making COVID-19 vaccine available for children will be a milestone achievement pave the way for reopening of schools resumption of outdoor activities for them, AIIMS Chief Dr Randeep Guleria has said.


He said the data of phase two three trial of Bharat Biotech’s Covaxin on two to 18 years age group is expected by September. The vaccine can be available for children in India around that time following approval from the drug regulator, he said.


“If the Pfizer vaccine gets approval before that, then it can also be an option for children,” Dr Guleria told PTI on Saturday.


According to a senior government official, pharmaceutical major Zydus Cadila is also likely to soon apply to the Drugs Controller General of India for emergency use authorisation for its COVID-19 vaccine ZyCoV-D, which it claims can be given to both adults children.


“So, if the Zydus vaccine gets approval, it will be another option,” Dr Guleria said.


He stressed that though children mostly have mild infections of COVID-19 some even are asymptomatic, they can be carriers of the infection.


Underscoring that there has been a major loss in studies in the last one-and-half years on account of the COVID-19 pandemic, the AIIMS chief said, “Schools have to be reopened vaccination can play an important role in that.”

Vaccination is the way out from the pandemic, he said.


The government has recently cautioned that even though COVID-19 has not impacted children greatly till now, that can increase if there is a change in the behaviour of the virus or in epidemiology dynamics. It said that preparations are being made to deal with any such situation.


A national expert group has been formed to review COVID-19 infections among children approach the pandemic in a new way reinforce the nation’s preparedness for it.


On the issue of vaccinating children, NITI Aayog member (Health) Dr V K Paul recently said, “Child cohort is not a small one. My rough guess is that if it is between 12 to 18 years, this itself is about 13 to 14 crore population for which we will need about 25-26 crore doses.”








He further shared that not only Bharat Biotech’s Covaxin, Zydus Cadila’s vaccine is also being tested on children.


“So when Zydus comes for licensure soon, maybe we have enough data to take a view on whether the vaccine can be given in children,” Paul said.

(Only the headline picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information commentary on developments that are of interest to you have wider political economic implications for the country the world. Your encouragement constant feedback on how to improve our offering have only made our resolve commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed updated with credible news, authoritative views incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better more relevant content. We believe in free, fair credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism subscribe to Business Standard.

Digital Editor



Source link